A new paper led by Alex Zhavoronkov, whose AI-based pharma company has much of its brain trust in Montreal, argues that tests of a potential Insilico treatment for a lung condition suggest clinical trials for drugs aimed at diseases related to aging should also look at whether those drugs can reverse aging more generally. (The Logic)

Talking point: A clinical trial has found that a treatment Insilico is working on for idiopathic pulmonary fibrosis, a lung ailment often tied to aging, helps with that illness and also broadly reduces blood chemicals believed to signal that people’s bodies are just wearing out. That might mean Insilico’s drug, rentosertib, can help with other age-related conditions. Zhavoronkov told The Wall Street Journal that trials for such “dual-purpose drugs” are more commercially viable than general anti-aging work is.

Sponsored Content

How to shift your workforce from AI experimentation to adoption

By Jessica Aftimus Rosa

The real-world economic offshoots of sovereign AI

By Deborah Aarts

Increasing healthcare access across Canada

By Deborah Aarts

Paid promotional content